Alexion Pharmaceuticals (NASDAQ: ALXN) was founded in 1992 and is headquartered in Cheshire, Connecticut, USA. It has 3,121 full-time employees. It is an American biopharmaceutical company focused on the development of rare disease treatments (orphan drugs).
Alexion Pharmaceuticals (ALXN):
Alexion Pharmaceutical Company is a biopharmaceutical company engaged in the research and development, production and sales of therapeutic drugs for cardiovascular diseases, autoimmune system, and neurological diseases, and diseases caused by the human immune system. The company has two main products: eculizumab and pexelizumab, which are used to treat acute cardiopulmonary inflammation and rheumatoid arthritis.
Alexion (translation: Alexion Pharmaceuticals or Ruisong Pharmaceuticals) is committed to treating patients suffering from serious and fatal rare diseases with breakthrough technological innovations. Alexion scientists are among the first to discover the role and potential of terminal complement inhibition in disease treatment. A group of proteins in the terminal complement system play an important role in the human immune response and can damage healthy tissues and organs in some patients.
Alexion has developed the first terminal complement inhibitor—Soliris (eculizumab, trade name “Sully TM”). At present, the drug has been approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in more than 40 countries around the world, and approved for the treatment of atypical hemolytic uremic syndrome (aHUS) in the United States and the European Union. Alexion is stepping up the research and development of Soliris and other products in a series of rare and serious diseases.
Alexion Pharmaceuticals (ALXN) investment:
Biopharmaceutical company Alexion Pharmaceuticals (ALXN) announced on 2015-05-06 that it will acquire competitor Synageva Biopharma ( GEVA ) for US$115 in cash per share and 0.6581 shares of ALXN stock , equivalent to US$230 per share of GEVA and a net cash value of US$8.4 billion. . The merger has been unanimously approved by the board of directors of both parties. ALXN intends to accelerate revenue growth through this acquisition and diversify its profits. ALXN received financial support from Bank of America Merrill Lynch and JPMorgan Chase for this merger .
One of ALXN’s main products is a drug called Soliris, which treats orphan disease, which brought the company $20 in sales last year, and GEVA also has a similar drug called Kanuma.
It is recommended that investors continue to pay attention to the trends of these two stocks.